1.
Stanisic S, Bertolotto A, Berto P, Di ProcoloP, Morawski J. The cost-effectiveness of alemtuzumab in the management of relapse-remitting multiple sclerosis in Italy. GRHTA [Internet]. 10Apr.2019 [cited 2Apr.2020];6(1). Available from: https://journals.aboutscience.eu/index.php/grhta/article/view/465